Annexon Inc

Annexon Biosciences (Nasdaq: ANNX) is a clinical-stage biopharmaceutical company developing a platform of targeted immunotherapies for neuroinflammatory diseases affecting nearly 10 million people worldwide. The company's scientific approach focuses on C1q, the initiating molecule of the classical complement pathway, which when misdirected can cause tissue damage and functional loss. Annexon's pipeline includes tanruprubart for Guillain-Barré syndrome (GBS), a life-threatening neuromuscular emergency affecting 150,000 people annually; vonaprument, an intravitreal antigen-binding fragment for geographic atrophy (GA), a cause of irreversible blindness affecting over 8 million patients globally; and ANX1502, a first-in-kind oral small molecule C1s inhibitor being evaluated in autoimmune conditions including cold agglutinin disease. The company has regulatory engagement on both sides of the Atlantic, with an EU Marketing Authorisation Application under review for tanruprubart and FastTrack and PRIME designations for vonaprument. Annexon is pre-revenue and funded through equity capital and a credit facility with Oxford Finance. Updated Aug 12, 2026